Abstract
While stereotactic body radiation therapy (SBRT) is an emerging treatment strategy for peripherally located inoperable early stage or recurrent non-small cell lung cancer (NSCLC), there is concern regarding treatment of central lesions with large radiation fraction sizes. Timmerman et al., reported an unacceptably high rate of toxicity for central lesions treated to 60-66 Gy in 3 fractions, with a 1-yr grade 3-5 toxicity rate of 25%, compared to only 6% for peripheral lesions (JCO 2006 Oct 20:24(30):4833-9).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
